Computacenter - Director/PDMR Shareholding
Incorporated in
Registration number: 03110569
LEI: 549300XSXUZ1I19DB105
ISIN: GB00BV9FP302
(the 'Company')
The following notifications are made under Article 19 of the Market Abuse Regulation ('MAR') relating to certain transactions in the shares of the Company by Directors of the Company, Persons Discharging Managerial Responsibilities ('PDMR') of the Company and Persons Closely Associated ('PCA') with the Directors and PDMRs.
Vesting of Awards, Exercise of Options and Subsequent Sale of Shares
Computacenter Performance Share Plan 2005
The Company announces that on
DIRECTOR |
Number of options awarded |
% Award Vested1 |
Number of options vested |
Number of options lapsed |
Number of options exercised |
Number of options held |
|
|
|
|
|
|
|
Mr M J Norris (Director) |
51,678 |
90.86% |
46,954 |
4,724 |
- |
46,954 |
|
|
|
|
|
|
|
1 Awards granted under the PSP Plan vest subject to the satisfaction of performance conditions at the end of a three year period. The level of vesting for PSP Awards granted in 2021 was 90.86% for the PSP Enhanced Plan. The PSP Award vested is subject to a two year holding period before they are released to the Director. |
The Company announces that on
DIRECTOR |
Number of shares vested2 |
Number of shares sold |
Number of shares retained |
Mr M J Norris (Director) |
7,527 |
7,527 |
- |
2 On
The relevant FCA notifications are set out below.
PDMR/PCA FCA Transaction Notification
1.
|
Details of Director/Person Discharging Managerial Responsibilities |
||
|
|
|
|
2. |
Reason for the notification
|
||
2(a)
|
Position/Status |
Chief Executive Officer |
|
2(b)
|
Initial Notification/ Amendment
|
Initial Notification |
|
3.
|
Details of the issuer
|
||
3(a)
|
|
|
|
3(b)
|
LEI |
549300XSXUZ1I19DB105 |
|
4. |
Details of the transaction(s): Section to be repeated for (i) each type of instrument, (ii) each type of transaction, (iii) each date and (iv) each place where transaction(s) have been conducted
|
||
4(a)
|
Description of the financial instrument
|
Ordinary shares of 7 5/9 pence in
ISIN: GB00BV9FP302
|
|
4(b)
|
Nature of Transaction
|
Ordinary Shares acquired following the vesting of a conditional award, made on
|
|
4(c)
|
Price(s) and Volume(s)
|
Price(s) (in GBP)
|
Volume(s) |
nil |
7,086 |
||
4(d)
|
Aggregated Information
Aggregated Volume and Price
|
nil |
7,086 |
4(e)
|
Date of the transaction
|
|
|
4(f)
|
Place of the transaction
|
Outside of a trading venue. The Ordinary Shares for the above-mentioned exercise were satisfied out of those held by the 2011
|
|
4. |
Details of the transaction(s): Section to be repeated for (i) each type of instrument, (ii) each type of transaction, (iii) each date and (iv) each place where transaction(s) have been conducted
|
||
4(a)
|
Description of the financial instrument
|
Ordinary shares of 7 5/9 pence in
ISIN: GB00BV9FP302
|
|
4(b)
|
Nature of Transaction
|
Ordinary Shares acquired as dividend equivalents related to the grant and vesting of a conditional award, made on
|
|
4(c)
|
Price(s) and Volume(s)
|
Price(s) (in GBP)
|
Volume(s) |
nil |
441 |
||
4(d)
|
Aggregated Information
Aggregated Volume and Price
|
nil |
441 |
4(e)
|
Date of the transaction
|
|
|
4(f)
|
Place of the transaction
|
Outside of a trading venue. The Ordinary Shares for the above-mentioned exercise were satisfied out of those held by the 2011
|
|
4. |
Details of the transaction(s): Section to be repeated for (i) each type of instrument, (ii) each type of transaction, (iii) each date and (iv) each place where transaction(s) have been conducted
|
||
4(a)
|
Description of the financial instrument
|
Ordinary shares of 7 5/9 pence in
ISIN: GB00BV9FP302
|
|
4(b)
|
Nature of Transaction
|
Sale of Ordinary Shares. Sold all 7,527 Shares from the conditional award vested, and dividend equivalent shares acquired, under the
|
|
4(c)
|
Price(s) and Volume(s)
|
Price(s) (in GBP)
|
Volume(s) |
27.14 |
7,527 |
||
4(d)
|
Aggregated Information
Aggregated Volume and Price
|
27.14 |
7,527 |
4(e)
|
Date of the transaction
|
|
|
4(f)
|
Place of the transaction
|
XLON |
|
4. |
Details of the transaction(s): Section to be repeated for (i) each type of instrument, (ii) each type of transaction, (iii) each date and (iv) each place where transaction(s) have been conducted
|
||
4(a)
|
Description of the financial instrument
|
Ordinary shares of 7 5/9 pence in
ISIN: GB00BV9FP302
|
|
4(b)
|
Nature of Transaction
|
Ordinary Shares acquired following exercise of a nil-cost option awarded under the Computacenter Performance Share Plan 2005 (the 'PSP Award'). There was no price payable on the grant or exercise of the PSP Award. Vesting of the PSP Award was subject to the achievement of a performance condition over a three year period and released after a two year holding period.
|
|
4(c)
|
Price(s) and Volume(s)
|
Price(s) (in GBP)
|
Volume(s) |
Nil |
90,604 |
||
4(d)
|
Aggregated Information
Aggregated Volume and Price
|
Nil |
90,604 |
4(e)
|
Date of the transaction
|
|
|
4(f)
|
Place of the transaction
|
Outside of a trading venue. The Ordinary Shares for the above-mentioned exercise were satisfied out of those held by the 2011
|
|
4. |
Details of the transaction(s): Section to be repeated for (i) each type of instrument, (ii) each type of transaction, (iii) each date and (iv) each place where transaction(s) have been conducted
|
||
4(a)
|
Description of the financial instrument
|
Ordinary shares of 7 5/9 pence in
ISIN: GB00BV9FP302
|
|
4(b)
|
Nature of Transaction
|
Sale of Ordinary Shares. Sold all 90,604 shares acquired following the exercise of a nil-cost option vested under the Computacenter Performance Share Plan 2005.
|
|
4(c)
|
Price(s) and Volume(s)
|
Price(s) (in GBP)
|
Volume(s) |
27.017888 |
90,604 |
||
4(d)
|
Aggregated Information
Aggregated Volume and Price
|
27.017888 |
90,604 |
4(e)
|
Date of the transaction
|
|
|
4(f)
|
Place of the transaction
|
XLON
|
Enquiries:
|
|
Company Secretary |
|
|
|
Address: |
Hatfield AL10 9TW |
Telephone: |
+44 (0) 7385 514 715 |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the